Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
January 30, 2026
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
January 28, 2026
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
January 8, 2026
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
December 22, 2025
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
December 10, 2025
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
December 3, 2025